«In Europe, there are 165 million living with a brain disorder, and one in three people are predicted to suffer with some neurological disorder during their lifetime. Each year, the cost of treating brain disorders equates to 35% of Europe’s total disease burden — that’s almost €800 billion. 

INBRAIN is a spin off from the Graphene Flagship, one of the largest European research initiatives, and its partners the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA), in Spain. Established in 2019, INBRAIN uses technology developed by Graphene Flagship partners ICN2, ICREA and the University of Manchester to develop smart devices for patients with neuronal disorders, like Parkinson’s or epilepsy.»

Article written by Med-Tech Innovation News



Med-Tech Innovation News